Dra. Elena López Miranda

2023-actualidad|Médico adjunto del Servicio de Oncología Médica, Unidad de Tumores de Mama, Hospital Ruber Interacional.

2013-actualidad|Médico adjunto del Servicio de Oncología Médica del Hospital Ramón y Cajal de Madrid, Sección de Cáncer de Mama y Tumores Ginecológicos.,

2007- 2012|Médico adjunto, Servicio de Oncología Médica del Hospital Universitario de Móstoles.

2003-2007|Formación MIR en Oncología Médica, Hospital Universitario Ramón y Cajal de Madrid.

Investigación:

Implicada en proyectos de investigación en cáncer de mama.

Participación como investigadora en numerosos ensayos clínicos de fase I a fase III. Algunos de los mas relevantes son:

• An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer (ELECTRA).
• Phase Ia/b Study of Giredestrant ±Palbociclib and ±LHRH Agonist in Estrogen Receptor-positive, HER2-negative, Locally Advanced/Metastatic Breast Cancer.
• Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer.
• A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05).
  • A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of giredestrant plus everólimus compared with exemestane plus everolimus in patients with estrogen receptor-positive HER"-negative, locally advanced or metastatic breast cancer.

Docencia:

Implicada en actividades docentes de pregrado, participando como docente en la asignatura de Oncología Médica y en Master de Cáncer Cutáneo de la Universidad de Alcalá.

2022|Cytological and molecular characterization of secretory breast carcinoma.Diagnostic Cytopathology. 2022.

2021|Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA- Breast) Study. Cancers .

2021|Pembrolizumab plus eribulin in hormone receptor positive, HER2- negative, locally recurrent or metastatic breast cancer: A Phase II, single-arm trial (KELLY)José European Journal of cancer. Mayo 2021.

2020|Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. Cáncers ,25 Nov 2020.

2019|High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. Cancers . Enero 2019.

2022|Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study. ESMO 2022.

2021|Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer. SABCS 2021.

2021|Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL- NICD gene transcription factor complex in human cancers., ASCO 2021.

2021|Impact of HER2 low (H2L) expression on prognosis in luminal locally advanced or metastatic breast cancer (BC): ESMO 2021.

Sociedades Científicas a las que pertenece:

-Sociedad Española de Oncología Médica (SEOM)

-Sociedad Europea de Oncología Médica (ESMO).

Así como a los grupos españoles de investigación en cáncer de mama SOLTI y GEICAM.